A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization.
Coulaud
I P
IP
Gougeon
M L
ML
Gomard
E
E
Descamps
D
D
Lebon
P
P
Aboulker
J P
JP
Bizzini
B
B
Zagury
D
D
D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000276:immunology / Q000627:therapeutic use*; D010455:Peptides / Q000276:immunology / Q000627:therapeutic use; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D016915:AIDS Vaccines; D004338:Drug Combinations; D007370:Interferon Type I; D010455:Peptides; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic